Peptide Catalog
9 molecules tracked · Status taxonomy per revamp spec
Showing hardcoded catalog from spec. Once
peptide_catalog table has rows, this page will query live data.LiveTrackingNear CuspPausedDiscontinued
| Name | Status | Category | Molecule | Notes |
|---|---|---|---|---|
| Semaglutide | Live | GLP-1 / Weight Loss | Semaglutide | Core Bask product. Compounded versions available through Hallandale. Ozempic / Wegovy / Rybelsus brand names. |
| Tirzepatide | Live | GLP-1 / Weight Loss | Tirzepatide | Dual GIP/GLP-1 agonist. Mounjaro / Zepbound. Growing Rx share. |
| Sermorelin | Live | Hormone / Longevity | Sermorelin | Growth hormone secretagogue. Established compounded peptide. |
| PT-141 (Bremelanotide) | Live | Sexual Health | Bremelanotide | FDA-approved as Vyleesi. Compounded versions tracked through Bask. |
| NAD+ | Near Cusp | Longevity | Nicotinamide Adenine Dinucleotide | IV and subcutaneous variants tracked. Compounding access widening. Several delivery mechanisms. |
| Retatrutide | Tracking | GLP-1 / Weight Loss | Retatrutide | Triple agonist (GIP/GLP-1/glucagon). Phase 3 readout expected 2026. Negative PDP candidate. |
| Ipamorelin | Tracking | Hormone / Longevity | Ipamorelin | GH secretagogue. Often combined with CJC-1295. |
| CJC-1295 | Tracking | Hormone / Longevity | CJC-1295 | Long-acting GHRH analog. Combo candidate. |
| BPC-157 | Discontinued | Peptide / Recovery | Body Protection Compound 157 | FDA mass-compounding ban effective May 22, 2025. No longer available through compounding pharmacies. Monitor for reversal. |